DIA has made a strategic investment in Claritype, an AI-powered data integration platform, to enhance efficiency and decision-making in the dental analytics sector.

Information on the Target

Claritype is an innovative artificial intelligence (AI) data integration and analytics platform focused on the multi-site healthcare industry, particularly in dental practices. The platform provides a solution for the widespread issue of fragmented data across various systems, including practice management, accounting, and telecommunications. By utilizing advanced AI technology, Claritype helps provider organizations generate actionable insights and comprehensive reports that facilitate real-time strategic decision-making.

Launched in late 2024, Claritype's flagship product, Visio360, empowers dental providers to harness the power of structured data from multiple enterprise systems. This allows practices to efficiently analyze their data through sophisticated analytics, dashboards, and visualization tools, thereby turning raw data into strategic advantages while avoiding the disruptive costs associated with converting acquired practices to a unified practice management system.

Industry Overview

The dental analytics sector operates within the broader multi-site healthcare market, which exceeds $1 trillion in value. This industry has been facing significant challenges due to data fragmentation, making it difficult for provider organiz

View Source

Similar Deals

Rittenhouse Ventures S2N Health, Inc.

2025

Other VC Medical Software & Technology Services United States of America
Mubadala Capital Tenvie Therapeutics

2025

Other VC Bio Therapeutic Drugs United States of America
Comcast Ventures Sword Health

2025

Other VC Home Healthcare Services United States of America
Dental Innovation Alliance (DIA) Perceptive

2025

Other VC Advanced Medical Equipment & Technology (NEC) United States of America
One Eight Capital Sollis Health

2025

Other VC Ambulance & Emergency Services United States of America
Alzheimer’s Drug Discovery Foundation Transposon Therapeutics

2025

Other VC Proprietary & Advanced Pharmaceuticals United States of America

DIA

invested in

Claritype

in 2025

in a Other VC deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert